BRIEF published on 10/15/2024 at 07:35, 1 month 8 days ago Conclusion du recrutement pour l'essai clinique de MaaT Pharma Essai Clinique MaaT Pharma MaaT013 Avis DSMB Traitement AGvH
BRIEF published on 10/15/2024 at 07:35, 1 month 8 days ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
PRESS RELEASE published on 10/15/2024 at 07:30, 1 month 8 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte. Premiers résultats attendus en janvier 2025 MaaT Pharma MaaT013 Phase 3 ARES Maladie Aiguë Greffon Contre L'hôte
PRESS RELEASE published on 10/15/2024 at 07:30, 1 month 8 days ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
PRESS RELEASE published on 09/20/2024 at 09:07, 2 months 2 days ago Rapport Financier Semestriel 2024
BRIEF published on 09/04/2024 at 07:35, 2 months 19 days ago MaaT Pharma annonce sa participation à des conférences investisseurs et médicales en septembre Investisseurs Conférence Médicale Thérapies MET Transplantation Cellulaire Cancers
BRIEF published on 09/04/2024 at 07:35, 2 months 19 days ago MaaT Pharma Announces Participation in Investor and Medical Conferences in September Investors Cancers Medical Conference MET Therapies Cell Transplantation
PRESS RELEASE published on 09/04/2024 at 07:30, 2 months 19 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce sa participation aux conférences investisseurs et médicales en septembre, avec des présentations lors du Congrès annuel de la Society of Hematologic Oncology à Houston et à d'autres événements internationaux Conférences Investisseurs Microbiote MaaT Pharma Cancers
BRIEF published on 05/15/2024 at 07:35, 6 months 8 days ago MaaT Pharma clôture avec succès une levée de fonds de 19,2 millions d'euros Investissement Biotechnologie Essais Cliniques Levée De Fonds MaaT Pharma
BRIEF published on 05/15/2024 at 07:35, 6 months 8 days ago MaaT Pharma successfully completes a fundraising of 19.2 million euros Biotechnology Fundraising Investment MaaT Pharma Clinical Tests
Published on 11/22/2024 at 23:55, 9 hours 5 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 30 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 9 hours 55 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 30 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 14 hours 46 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 15 hours 7 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 5 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:15, 16 hours 45 minutes ago NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/21/2024 at 06:58, 2 days 2 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
